预约演示
更新于：2026-06-08
Reslizumab
瑞替珠单抗
更新于：2026-06-08
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2016-03-23), |
最高研发阶段(中国)申请上市 |
特殊审评孤儿药 (美国)、孤儿药 (韩国) |
登录后查看时间轴
结构/序列
Sequence Code 199184H
来源: *****
Sequence Code 199204L
来源: *****
关联
30
项与 瑞替珠单抗 相关的临床试验CTIS2025-524741-28-00
BIOlogical treatment GRAdual Interval Longing in severe Asthma (BIO-GRAIL)
NCT06024707
Early Detection of the Effectiveness of Treatment With Biologicals in Patients With Severe Asthma Using Fluctuation Analysis of Biomarkers
NCT04665141
Similarities and Differences of Biological Therapies for Severe Asthma.
100 项与 瑞替珠单抗 相关的临床结果
登录后查看更多信息
100 项与 瑞替珠单抗 相关的转化医学
登录后查看更多信息
100 项与 瑞替珠单抗 相关的专利（医药）
登录后查看更多信息
374
项与 瑞替珠单抗 相关的文献（医药）2026-02-01Journal of Allergy and Clinical Immunology-In Practice
Overview of Biologics Targeting Type 2 Inflammation in Respiratory Disease
Review
作者: Wechsler, Michael E ; Carr, Tara F ; Stevens, Whitney W
The development, introduction, and widespread use of type 2-targeting biologics for respiratory disease has been of dramatic and unprecedented benefit to patients, improving disease control, reducing morbidity, and allowing for avoidance of more toxic therapies such as reliance on chronic systemic corticosteroids. Developed to treat more severe forms of asthma, the available biologics-benralizumab, dupilumab, mepolizumab, omalizumab, reslizumab, and tezepelumab-have been successfully applied to treat other diseases of the upper and lower airways. Indeed, multiple different biologics are now approved by the Food and Drug Administration for each general clinical indication: severe asthma, chronic obstructive pulmonary disease, eosinophilic granulomatosis with polyangiitis, and chronic rhinosinusitis with nasal polyposis. Clinically, the selection of a type 2-targeting biologic for respiratory disease starts with the confirmation of a specific diagnosis, assessment of responsiveness to previous medical (and surgical) therapies, and determination whether underlying type 2 inflammation is present. Other critical considerations include route of administration, accessibility, insurance coverage, and patient preference. In some cases, there may be only 1 biologic available for a patient. However, as often is the case, patients may indeed qualify for, or potentially benefit from, more than 1 treatment. Selecting the right treatment-that which is most effective-can be a challenge. In this review, we provide practical and evidence-based recommendations about selecting a type 2 biologic across the spectrum of respiratory diseases.
2026-02-01SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE
Glucocorticoid Treatment in Severe Asthma
Review
作者: Espejo-Castellanos, David ; Muñoz-Gall, Xavier ; Pilia, María Florencia ; Ojanguren-Arranz, Iñigo ; Romero-Mesones, Christian
Abstract:
Severe asthma affects approximately 3% to 10% of the asthmatic population and is characterized by persistent symptoms and frequent exacerbations despite high-intensity therapy. Historically, glucocorticoids (GCs) have been the mainstay of treatment due to their broad anti-inflammatory effects. However, long-term systemic GC use is associated with substantial toxicity and heterogeneous clinical response, largely influenced by underlying inflammatory endotypes. Type 2 (T2) asthma, marked by eosinophilia and cytokines such as IL-4, IL-5, and IL-13, generally responds well to GCs. In contrast, non-T2 phenotypes, often associated with neutrophilic inflammation, obesity, or smoking, exhibit GC resistance. Molecular mechanisms underlying GC resistance include GRβ overexpression, impaired GRα nuclear translocation via mitogen-activated protein kinase (MAPK) activation, and histone deacetylase-2 (HDAC2) inactivation by oxidative stress. Therapeutic strategies for severe asthma involve maximizing inhaled corticosteroids (ICSs) and adding long-acting bronchodilators or biologics before considering maintenance oral corticosteroids (OCSs). Despite these guidelines, OCS overuse remains common, with many patients exposed to cumulative doses associated with severe adverse effects. These include osteoporosis, diabetes, infections, neuropsychiatric symptoms, and adrenal suppression. Therefore, reducing systemic GC exposure is a key objective in modern asthma management. Biologic therapies targeting IgE (omalizumab), IL-5 (mepolizumab, reslizumab), IL-5Rα (benralizumab), IL-4Rα (dupilumab), and thymic stromal lymphopoietin (tezepelumab) have shown substantial OCS-sparing effects in clinical trials, enabling dose reduction or discontinuation in many patients with steroid-dependent asthma. These agents, aligned with precision medicine principles, allow for phenotype-specific treatment and improved safety profiles. Future efforts should focus on improving biomarker-driven treatment selection, expanding non-T2 therapeutic options, and implementing steroid stewardship protocols. In conclusion, while GCs remain essential for acute exacerbations and as bridging therapy, their chronic use should be minimized. Biologic therapies offer a transformative opportunity to reduce GC burden, improving long-term outcomes and quality of life in patients with severe asthma.
2026-01-01The journal of allergy and clinical immunology. Global
Real-world outcomes after anti–IL-5/anti–IL-5Rα treatment for hypereosinophilic syndrome: Systematic literature review
Article
作者: Ding, Ning ; Chen, Stephanie Yanjing ; Stokes, Michael ; Rowell, Jennifer ; Jain, Priya ; Edmonds, Christopher
Background:
Anti-IL-5/anti-IL-5 receptor alpha (anti-IL-5/anti-IL-5Rα) treatments have potential to improve outcomes in hypereosinophilic syndrome (HES), as demonstrated in clinical trials.
Objective:
We sought to understand the real-world outcomes of anti-IL-5/anti-IL-5Rα treatments in patients with HES.
Methods:
This systematic literature review searched English-language articles (November 4, 2015, to October 31, 2023) and conference abstracts (January 1, 2021, to October 31, 2023) from MEDLINE/Embase and select conferences for publications containing outcomes for patients with HES receiving anti-IL-5 (mepolizumab [approved], reslizumab) or anti-IL-5Rα (benralizumab) treatment in the real world. Meta-analyses and clinical trials were excluded. Outcomes included treatment response, blood eosinophil (bEOS) counts, and oral corticosteroid (OCS) receipt. No formal bias assessment was conducted.
Results:
Five cohort studies (192 participants) and 55 case reports (70 participants) were identified. In cohort studies, median age was 44.0 to 61.8 years; 33.3% to 62.9% were female, and 45.5% to 100% had idiopathic HES. Mean (standard deviation) age in case reports (n = 68/70) was 38.5 (23.7) years; 40.0% (n = 28/70) were female, and 67.2% (n = 39/58) had idiopathic HES. Across 4 cohort studies, most patients had reduced or no HES flares after mepolizumab or benralizumab. In patients from case reports, 13 had HES flares (mepolizumab, n = 12/54; benralizumab, n = 1/13) after anti-IL-5/anti-IL-5Rα initiation. Mean bEOS counts were reduced by 53.0% to 100% across 3 cohort studies and by 95.0% in case reports. Of those receiving benralizumab or mepolizumab, OCS dose was reduced in 49.0% to 100% of patients from cohort studies, and by ≥50% in 29 of 70 patients from case reports.
Conclusion:
Real-world anti-IL-5/anti-IL-5Rα therapy in HES is associated with fewer flares as well as reductions in bEOS counts and OCS dose, although confirmatory studies in larger populations are needed.
82
项与 瑞替珠单抗 相关的新闻（医药）2026-06-03
2026-05-29
100 项与 瑞替珠单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肺嗜酸性粒细胞增多 | 欧盟 | 2016-08-15 | |
| 肺嗜酸性粒细胞增多 | 冰岛 | 2016-08-15 | |
| 肺嗜酸性粒细胞增多 | 列支敦士登 | 2016-08-15 | |
| 肺嗜酸性粒细胞增多 | 挪威 | 2016-08-15 | |
| 嗜酸性粒细胞性哮喘 | 加拿大 | 2016-07-20 | |
| 哮喘 | 美国 | 2016-03-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 支气管炎 | 临床3期 | 加拿大 | 2015-10-01 | |
| 严重持续性哮喘 | 临床3期 | 加拿大 | 2015-10-01 | |
| 气道病变 | 临床3期 | 法国 | 2014-10-31 | |
| 嗜酸粒细胞性食管炎 | 临床3期 | 美国 | 2008-07-01 | |
| 嗜酸粒细胞性食管炎 | 临床3期 | 加拿大 | 2008-07-01 | |
| Churg-Strauss综合征 | 临床2期 | 美国 | 2017-09-12 | |
| 重度哮喘 | 临床2期 | 西班牙 | 2017-04-20 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 33 | 鏇膚淵遞鑰餘衊選簾積(廠選鏇顧艱醖積鑰糧醖) = 鬱觸積遞鬱選鏇齋鑰艱 夢構衊壓製鹽壓鑰觸壓 (鹹窪網餘築構繭鏇顧觸, 2.74) | 积极 | 2023-09-09 | |||
(previous MA) | 鏇膚淵遞鑰餘衊選簾積(廠選鏇顧艱醖積鑰糧醖) = 夢築醖願製艱廠糧蓋艱 夢構衊壓製鹽壓鑰觸壓 (鹹窪網餘築構繭鏇顧觸, 14.93) | ||||||
N/A | 5 | 壓遞淵淵網顧積膚憲醖(壓醖觸範簾餘鏇壓獵鬱) = 蓋鹹壓選構繭艱艱選鹽 衊網夢範遞觸構鹽選顧 (顧餘膚觸齋艱夢壓夢餘 ) | 积极 | 2023-09-09 | |||
N/A | 嗜酸性粒细胞性哮喘 interleukin-5 (IL-5) | 24 | 鏇製憲衊製範膚願簾簾(獵憲範顧範鬱鹹繭壓鬱) = 選齋窪鑰網製範襯艱艱 遞顧鑰積積鏇夢蓋壓製 (構鬱鏇鏇網襯鹽鹹壓鬱 ) | 积极 | 2022-09-04 | ||
N/A | - | 衊夢積膚夢憲觸膚範觸(積製製蓋鏇衊鏇壓觸襯) = 鏇繭簾夢選壓築夢衊襯 範鏇顧觸鹹選餘鑰遞蓋 (築衊壓網繭鑰蓋壓醖壓 ) | 积极 | 2022-09-04 | |||
衊夢積膚夢憲觸膚範觸(積製製蓋鏇衊鏇壓觸襯) = 夢壓願構願襯蓋遞糧糧 範鏇顧觸鹹選餘鑰遞蓋 (築衊壓網繭鑰蓋壓醖壓 ) | |||||||
临床2期 | 10 | 醖繭顧醖醖鏇構艱醖繭(糧繭選獵獵衊鬱醖構範) = 齋餘鬱製糧網壓鏇膚艱 醖鑰廠衊壓鏇襯選壓壓 (築簾壓糧獵選艱糧夢遞 ) | 积极 | 2021-06-01 | |||
临床3期 | 177 | 蓋簾壓齋鹽醖鑰繭積願(膚製醖窪醖簾積網顧艱): OR = 1.23 (95% CI, 0.70 ~ 2.16), P-Value = 0.47 | 不佳 | 2020-05-01 | |||
Placebo | |||||||
N/A | 477 | 蓋膚觸餘築衊夢鹹觸醖(鬱鹹範繭醖衊淵製遞製) = 憲窪蓋遞鏇齋鏇齋廠艱 顧廠繭襯製築選簾壓願 (遞遞襯糧築艱鹹獵製襯 ) 更多 | - | 2019-09-28 | |||
Placebo | 鑰網簾觸糧網艱遞範廠(積醖蓋鬱襯夢鏇築鏇構) = 壓獵獵簾遞壓壓願餘觸 構觸糧積簾憲膚壓繭製 (觸壓鏇餘鬱壓遞齋獵觸 ) | ||||||
临床4期 | 5 | 膚鏇憲鏇範獵鬱夢餘齋(遞鏇範獵網鬱膚艱範構) = 餘窪簾鹹鹽窪蓋餘觸窪 顧鏇遞鹽鏇窪選構夢廠 (衊憲築淵鬱網築範範憲, 191.83) 更多 | - | 2019-08-06 | |||
临床3期 | 391 | 膚餘餘繭艱顧鏇築鏇範(鏇鏇膚獵顧鏇窪觸繭艱) = 製願製膚淵襯鑰壓鬱遞 製壓製製壓鬱膚鑰鬱製 (鏇艱齋醖製選淵製壓蓋, 築夢顧衊餘醖鹹鏇艱鹽 ~ 糧積窪網醖醖鹹餘範選) 更多 | - | 2019-03-21 | |||
临床3期 | 468 | Placebo | 憲觸糧窪獵願鑰蓋顧鏇(簾膚糧顧顧繭顧願築窪) = 餘繭壓衊夢鹹壓壓鏇夢 築範鑰遞網簾網餘衊遞 (獵顧淵鏇艱築選顧選積, 膚積壓觸鑰簾網積鏇簾 ~ 廠廠選淵衊艱襯蓋顧觸) 更多 | - | 2019-02-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用